欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Navitoclax_923564-51-6_产品详情
923564-51-6
  • names:

    Navitoclax

  • CAS号:

    923564-51-6

    MDL Number:
  • MF(分子式): C47H55ClF3N5O6S3 MW(分子量): 974.61
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Navitoclax
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM001604-10mg 10mg 99.97% ¥ 1296.00 ¥ 1296.00 2-3天
- +
¥ 0.00
YZM001604-5mg 5mg 99.97% ¥ 845.00 ¥ 845.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 923564-51-6
Inchi
InchiKey
分子式 Formula C47H55ClF3N5O6S3
分子量 Molecular Weight 974.61
溶解度Solubility 生物体外In Vitro:DMF : ≥ 100 mg/mL(102.61 mM)DMSO溶解度75 mg/mL(76.95 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
Navitoclax(CAS:923564-51-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Navitoclax (ABT-263) 为有效,可口服的Bcl-2抑制剂,可与Bcl-xL,Bcl-2, Bcl-w等多种Bcl-2家族蛋白结合,Ki值小于 1 nM
IntroductionNavitoclax (ABT63) is a potent and orally activeBcl family proteininhibitor that binds to multiple antipoptotic Bcl family proteins, such as BclL, Bcl and Bcl, with aKiof less than 1 nM.
Application1
Application2
Application3
Navitoclax (ABT-263) 为有效,可口服的Bcl-2抑制剂,可与Bcl-xL,Bcl-2, Bcl-w等多种Bcl-2家族蛋白结合,Ki值小于 1 nM。Navitoclax (ABT-263) is a potent and orally activeBcl-2 family proteininhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with aKiof less than 1 nM.
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1181-1189.
【2】.Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11(4):1026-1035.
【3】.Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents